NYSE:EW Edwards Lifesciences (EW) Stock Price, News & Analysis $81.26 -0.13 (-0.15%) Closing price 03:59 PM EasternExtended Trading$80.09 -1.18 (-1.45%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Edwards Lifesciences Stock (NYSE:EW) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Edwards Lifesciences alerts:Sign Up Key Stats Today's Range$80.33▼$81.9450-Day Range$77.11▼$85.7652-Week Range$72.30▼$87.89Volume3.31 million shsAverage Volume5.55 million shsMarket Capitalization$46.79 billionP/E Ratio43.23Dividend YieldN/APrice Target$95.65Consensus RatingModerate Buy Company Overview Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery. In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams. The company also produces hemodynamic monitoring platforms and consumables intended for perioperative and intensive care settings to support patient management during high-acuity procedures. Customers include hospitals and health systems across multiple geographies, and Edwards distributes its products globally in markets such as North America, Europe and the Asia-Pacific region. Edwards Lifesciences has a long-standing emphasis on research, clinical evidence and product innovation, pursuing clinical trials and regulatory approvals to expand indications for existing therapies and to develop new treatments for other forms of structural heart disease. Its business model combines manufacturing, direct sales and partnerships to support training, clinical adoption and post-market surveillance. The company’s strategic focus remains on advancing less-invasive cardiac therapies and improving outcomes for patients with valvular and critical cardiovascular conditions.AI Generated. May Contain Errors. Read More Edwards Lifesciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks79th Percentile Overall ScoreEW MarketRank™: Edwards Lifesciences scored higher than 79% of companies evaluated by MarketBeat, and ranked 101st out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingEdwards Lifesciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on 3 strong buy ratings, 16 buy ratings, 9 hold ratings, and no sell ratings.Upside PotentialEdwards Lifesciences has a consensus price target of $95.65, representing about 17.7% upside from its current price of $81.27.Amount of Analyst CoverageEdwards Lifesciences has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Edwards Lifesciences' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth11.67% Earnings GrowthEarnings for Edwards Lifesciences are expected to grow by 11.67% in the coming year, from $3.00 to $3.35 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Edwards Lifesciences is 43.23, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.59.Price to Earnings Ratio vs. SectorThe P/E ratio of Edwards Lifesciences is 43.23, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.89.Price to Earnings Growth RatioEdwards Lifesciences has a PEG Ratio of 2.00. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioEdwards Lifesciences has a P/B Ratio of 4.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Edwards Lifesciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.84% of the float of Edwards Lifesciences has been sold short.Short Interest Ratio / Days to CoverEdwards Lifesciences has a short interest ratio ("days to cover") of 1.66, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Edwards Lifesciences has recently increased by 12.94%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEdwards Lifesciences does not currently pay a dividend.Dividend GrowthEdwards Lifesciences does not have a long track record of dividend growth. News and Social Media4.5 / 5News Sentiment1.17 News SentimentEdwards Lifesciences has a news sentiment score of 1.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Edwards Lifesciences this week, compared to 8 articles on an average week.Search Interest17 people have searched for EW on MarketBeat in the last 30 days. This is an increase of 750% compared to the previous 30 days.MarketBeat Follows5 people have added Edwards Lifesciences to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Edwards Lifesciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,288,799.00 in company stock.Percentage Held by Insiders0.31% of the stock of Edwards Lifesciences is held by insiders.Percentage Held by Institutions79.46% of the stock of Edwards Lifesciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Edwards Lifesciences' insider trading history. Receive EW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EW Stock News HeadlinesAre Wall Street Analysts Bullish on Edwards Lifesciences Stock?May 14 at 2:51 PM | barchart.comEdwards Lifesciences' (NYSE:EW) Conservative Accounting Might Explain Soft EarningsMay 13 at 7:54 AM | finance.yahoo.comMillionaire warns: Move your money before May 15Larry Benedict - the trader who generated $274 million in client profits and beat the S&P 500 by 18 times in 2025 - says Trump's installation of a new Federal Reserve chair is triggering the most significant shift in U.S. markets in nearly 20 years. When the Fed cut rates in 2020, his readers had a chance at 62% gains. A 2022 rate-hike signal produced 117% in under a month. Now Benedict has identified the single ticker he believes will be at the center of the coming money flows - and he's revealing it free before May 15.May 14 at 1:00 AM | Brownstone Research (Ad)Edwards Lifesciences Corporation (EW) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 12 at 9:01 PM | seekingalpha.comEdwards Lifesciences (EW) is Benefitting from Expanding Its Aortic Valve FranchiseMay 11 at 9:30 AM | finance.yahoo.comEdwards Lifesciences Corp. stock underperforms Friday when compared to competitorsMay 8, 2026 | marketwatch.comEdwards Lifesciences Shareholders Approve Expanded Equity Incentive PlanMay 8, 2026 | tipranks.comInsider Selling: Edwards Lifesciences (NYSE:EW) VP Sells 1,019 Shares of StockMay 5, 2026 | insidertrades.comSee More Headlines EW Stock Analysis - Frequently Asked Questions How have EW shares performed this year? Edwards Lifesciences' stock was trading at $85.26 on January 1st, 2026. Since then, EW stock has decreased by 4.7% and is now trading at $81.2650. How were Edwards Lifesciences' earnings last quarter? Edwards Lifesciences Corporation (NYSE:EW) posted its quarterly earnings results on Thursday, April, 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.73 by $0.05. The business's revenue was up 16.7% compared to the same quarter last year. Read the conference call transcript. When did Edwards Lifesciences' stock split? Shares of Edwards Lifesciences split before market open on Friday, May 29th 2020.The 3-1 split was announced on Thursday, May 7th 2020. The newly minted shares were distributed to shareholders after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. Does Edwards Lifesciences have any subsidiaries? Edwards Lifesciences subsidiaries include CAS Medical Systems, Harpoon Medical, Valtech Cardio, CardiAQ Valve Technologies, BMEYE, Embrella Cardiovascular, Myocor, and others. Who are Edwards Lifesciences' major shareholders? Top institutional shareholders of Edwards Lifesciences include Bank of New York Mellon Corp (2.90%), Jennison Associates LLC (2.27%), Dimensional Fund Advisors LP (0.63%) and Allspring Global Investments Holdings LLC (0.36%). Insiders that own company stock include Larry L Wood, Jean-Luc M Lemercier, Kieran Gallahue, Steven R Loranger, Bernard J Zovighian, Scott B Ullem, Catherine M Szyman, Daniel J Lippis, Daveen Chopra, Heisz Leslie Stone, Donald E Bobo Jr, Robert WA Sellers, Wayne Markowitz and Michael A Mussallem. View institutional ownership trends. How do I buy shares of Edwards Lifesciences? Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Edwards Lifesciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Edwards Lifesciences investors own include Comcast (CMCSA), Chevron (CVX), Bristol Myers Squibb (BMY), Charles Schwab (SCHW), McKesson (MCK), Yum! Brands (YUM) and Toronto Dominion Bank (TD). Company Calendar Last Earnings4/23/2026Today5/14/2026Next Earnings (Estimated)7/23/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 EW's financial health is in the Green zone, according to TradeSmith. EW has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MED INSTRUMENTS Sub-IndustryHealth Care Equipment Current SymbolNYSE:EW CIK1099800 Webwww.edwards.com Phone(949) 250-2500Fax949-250-2525Employees16,000Year Founded1958Price Target and Rating Average Price Target for Edwards Lifesciences$95.65 High Price Target$110.00 Low Price Target$81.00 Potential Upside/Downside+17.7%Consensus RatingModerate Buy Rating Score (0-4)2.79 Research Coverage28 Analysts Profitability EPS (Trailing Twelve Months)$1.88 Trailing P/E Ratio43.23 Forward P/E Ratio27.09 P/E Growth2.04Net Income$1.07 billion Net Margins17.39% Pretax Margin20.59% Return on Equity15.19% Return on Assets11.71% Debt Debt-to-Equity Ratio0.06 Current Ratio4.42 Quick Ratio3.63 Sales & Book Value Annual Sales$6.07 billion Price / Sales7.71 Cash Flow$2.85 per share Price / Cash Flow28.54 Book Value$17.94 per share Price / Book4.53Miscellaneous Outstanding Shares575,800,000Free Float574,015,000Market Cap$46.79 billion OptionableOptionable Beta0.87 Social Links 7 Stocks to Ride The A.I. MegaboomWe are about to experience the greatest A.I. boom in stock market history... Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s. That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom. Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day. And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly... Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy. Get This Free Report This page (NYSE:EW) was last updated on 5/14/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | SponsoredMillionaire warns: Move your money before May 15Larry Benedict - the trader who generated $274 million in client profits and beat the S&P 500 by 18 times in 2...Brownstone Research | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredBlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edwards Lifesciences Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Edwards Lifesciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
